16 / 20
Page 48
Der Pharmacia Sinica
ISSN: 0976-8688
Eurosc i con Conference on
Medicinal Chemistry
and Biosimilars
M a r c h 2 5 - 2 6 , 2 0 1 9
B u d a p e s t , H u n g a r y
Medicinal Chemistry & Biosimilars 2019
P
atients need to make informed judgements on the value of biologic and biosimilar medicines as well as actively engage in
discussion and decision-taking with other stakeholders involved with their healthcare, most particularly with physicians and
pharmacists. Patients must have access to clear and impartial information about what biologic and biosimilar medicines are
and what the growing availability of these medicines will mean for them. Patients must be assured of the regulatory systems in
place to ensure safety, quality and efficacy and need to actively participate in post-approval monitoring and risk management,
including pharmacovigilance. Around the world many governments, regulators, healthcare systems and practitioners are finding
themselves challenged by the emergence of biosimilars, indeed in many countries, it is the patient organisations that are on the
front foot when it comes to getting biosimilars on the agenda. The alliance for safe biologic medicines has conducted seven
major surveys involving more than twenty countries focussed on the views and attitudes of physicians and pharmacists. Several
interestingly consistent responses have been received from the various survey samples. Resultant observations include: USA
physicians support labels with data to learn about and evaluate biosimilars; European doctors have insufficient knowledge of
biosimilars; Canadian physicians feel strongly about the need to retain sole prescription authority; and USA hospital pharmacists
are more likely to be “Very familiar” with biosimilars than retail pharmacists. For over a decade, the International Alliance of
Patients’ Organisations has been working with peak patient groups and regulators around the world to address the substantial
knowledge gap. Patient groups believe patients have the right to expect that the life of the patient remains the primary guiding
principle of biosimilar policy discussion above potential cost savings. This presentation will canvas these issues and will focus on
the most recent ASBM being a survey of physicians in Australia published in 2016 and revealing a mismatch between government
policy and physician practice.
smurby@bigpond.net.auPatient, physician and pharmacist perspectives: a
wider world view
Stephen Murby
Alliance for Safe Biologic Medicines, USA
Der Pharmacia Sinica 2019, Volume:10
DOI: 10.21767/0976-8688-C1-003